Product Description
GALE Antibody | 22-339 | ProSci
Host: Rabbit
Reactivity: Human, Mouse, Rat
Homology: N/A
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 129-348 of human GALE (NP_001121093.1) .
Research Area: Cancer, Signal Transduction
Tested Application: WB, IHC, IF
Application: WB: 1:500 - 1:2000
IHC: 1:50 - 1:200
IF: 1:10 - 1:100
Specificiy: N/A
Positive Control 1: SW480
Positive Control 2: SKOV3
Positive Control 3: HepG2
Positive Control 4: U-251MG
Positive Control 5: HeLa
Positive Control 6: Mouse liver
Molecular Weight: Observed: 38kDa
Validation: N/A
Isoform: N/A
Purification: Affinity purification
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Concentration: N/A
Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.
Alternate Name: GALE, SDR1E1
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form) . Multiple alternatively spliced transcripts encoding the same protein have been identified.